Introduction
============

Alzheimer's disease (AD) is pathologically characterized by the presence of senile plaques, polymorphous amyloid beta protein deposits and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. NFTs but not senile plaques are pathological hallmarks of a diverse array of neurodegenerative disorders other than AD, named tauopathies, such as progressive supranuclear palsy, corticobasal degeneration, and Pick's disease. In the hippocampi of tauopathy patients, granulovacuolar degeneration (GVD) bodies occur concomitantly with NFTs. GVD results in the formation of basophilic small inclusions in the perinuclear region of pyramidal neurones, comprising 3- to 5-μm-diameter spherical vacuoles surrounded by a halo-like clear zone. In addition to TDP-43, phosphorylated Smad2/3 (pSmad2/3), charged multivesicular body protein 2B (CHMP2B), several tau kinases including glycogen synthase kinase (GSK)-3β and cyclin-dependent kinase 5 (CDK5) also exist in GVD bodies implying that GVD bodies might be a site of tau modification that results in the formation of NFTs \[[@b1]--[@b5]\]. In pyramidal neurones, CDK5 immunoreactivity is found not only in GVD bodies, but also within NFTs as fine granules \[[@b5]\]. In accordance with the granules reported by Girardot *et al*., these CDK5-positive fine granules are spherical, stained homogenously, and of a similar size to intraluminal vesicles of GVD bodies, resembling the granules immunostained for the genuine raft protein flotillin-1 \[[@b6]\].

Recently, it was reported that GSK-3β and CDK5 are recruited to neuronal lipid raft microdomains upon stimulation \[[@b7],[@b8]\]. Lipid rafts, specialized plasma membrane domains, provide a platform for cell signalling \[[@b9]\]. Recent reports have also emphasized the importance of lipid rafts in the biogenesis and accumulation of amyloid protein implying that lipid rafts play a role in the pathogenesis of AD \[[@b10]--[@b13]\]. These lines of evidence suggest that CDK5-positive GVD bodies might be derived from lipid rafts.

Little is known about the lipid composition of GVD bodies or vesicles associated with NFTs \[[@b14]\]. Although cholesterol and sphingolipids are the major component of lipid rafts, phosphatidylinositol 4,5-bisphosphate \[PtdIns(4,5)P2\] is also a component of lipid rafts in the cell membrane \[[@b15]\], and is important for many aspects of membrane trafficking in neurones \[[@b16]\]. We hypothesized that lipid rafts are involved in the pathological mechanism underlying AD. Thus, in the present study, we investigated the distribution of specific phosphoinositides in the brains of AD patients and patients with other neurodegenerative diseases.

Materials and methods
=====================

Subjects
--------

Five cases of AD \[mean age = 74.2 years ± 6.18 standard error of the mean (SEM)\], three cases of myotonic dystrophy (MyD), six cases of amyotrophic lateral sclerosis (ALS), two cases each of Parkinson's disease with dementia (PDD) and multiple system atrophy (MSA), and one case each of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Pick's disease (PiD), and pantothenate kinase-associated neurodegeneration (PKAN) \[non-AD neurodegenerative disease; mean age = 67.8 years ± 8.86 SEM\], and four control cases (without neurodegenerative disorders according to clinical history and confirmed by neuropathological examination \[mean age = 64.0 years ± 11.6 SEM\]) were selected. The clinical profiles, GVD stages \[[@b17]\], phases of amyloid beta protein deposition phases \[[@b18]\], Braak NFT stages \[[@b19]\], frequencies of neuritic plaques according to the method of The Consortium to Establish a Registry for Alzheimer's Disease \[[@b20]\], and degrees of AD neuropathologic change \[[@b21]\] of these patients are shown in Table [1](#tbl1){ref-type="table"}. The use of human materials conformed to the ethical guidelines of Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. All AD cases fulfilled the quantitative neuropathological criteria for diagnosis of AD according to the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines for the neuropathologic assessment of AD; that is, Alzheimer Disease Neuropathologic Change scores of A3, B3 or C3 \[[@b21]\]. All MyD cases were compatible with clinical features, and the numbers of CTG repeats in the myotonin protein kinase gene were all \>3000.

###### 

Subject characteristics

  Case No.   Diagnosis   Gender   Age   GVD stage   Aβ phase   NFT stage   CERAD      AD neuropathologic change
  ---------- ----------- -------- ----- ----------- ---------- ----------- ---------- ---------------------------
   1         AD          M        73    5           5          6           Frequent   High
   2         AD          F        66    5           5          6           Frequent   High
   3         AD          F        75    5           5          6           Frequent   High
   4         AD          F        85    5           5          5           Frequent   High
   5         AD          F        72    5           5          5           Frequent   High
   6         MyD         M        57    4           3          2           Sparse     Low
   7         MyD         F        59    1           2          2           Sparse     Low
   8         MyD         M        48    1           3          1           Sparse     Low
   9         CBD         F        75    2           3          3           Frequent   Intermediate
  10         PSP         F        71    2           1          2           Sparse     Low
  11         PiD         M        66    1           0          3           None       Not
  12         PKAN        F        57    5           1          5           Sparse     Low
  13         PDD         M        86    1           4          2           Frequent   Low
  14         PDD         M        75    1           4          2           Frequent   Low
  15         MSA         F        73    1           5          2           Moderate   Low
  16         MSA         F        72    1           3          2           Frequent   Low
  17         ALS         F        70    1           1          2           Moderate   Low
  18         ALS         F        67    0           3          1           Sparse     Low
  19         ALS         M        77    0           3          0           Frequent   Low
  20         ALS         M        63    0           2          0           Sparse     Low
  21         ALS         M        65    0           0          0           None       Not
  22         ALS         F        72    0           5          0           Frequent   Low
  23         CON         F        49    0           0          0           None       Not
  24         CON         F        58    0           0          0           None       Not
  25         CON         F        69    0           0          0           None       Not
  26         CON         M        80    0           0          0           None       Not

CON, control case; AD, Alzheimer's disease case; MyD, myotonic dystrophy case; CBD, corticobasal degeneration case; PSP, progressive supranuclear palsy case; PiD, Pick's disease case; PKAN, pantothenate-kinase-associated neurodegeneration case; PDD, Parkinson's disease with dementia case; MSA, multiple system atrophy case; ALS, amyotrophic lateral sclerosis case; F, female; M, male; Age, age at death.

Brain tissue
------------

Autopsies were performed within 24 h of death. Brains and spinal cords were fixed in 10% (v/v) formalin for 3 weeks, and 7-μm thick paraffin-embedded sections were prepared for subsequent procedures. We sampled and analysed the medial temporal lobe, including the hippocampus and neocortex, of all cases for GVD bodies and NFTs, and the brain stem and spinal cord tissues of non-tauopathy cases, such as PDD, MSA, ALS and control cases, for Lewy bodies and Bunina bodies.

Immunohistochemistry
--------------------

The antibodies used for immunohistochemistry and immunofluorescence studies are listed in Table [2](#tbl2){ref-type="table"}. The sections were deparaffinized and rehydrated. For antigen retrieval, microwave treatment in distilled water for 10 min was performed, followed by washing in phosphate-buffered saline (PBS) for 3 min. Deparaffinized sections were then incubated with 3% H~2~O~2~ in PBS for 60 min to eliminate endogenous peroxidase activity in tissues. Each section was incubated with primary antibodies overnight at 4°C. The sections were then washed three times in PBS and incubated with horseradish peroxidase (HRP)-conjugated anti-mouse antibody or anti-rabbit antibody for 30 min at room temperature. The avidin--biotin complex method was used to detect the mouse monoclonal IgM-type antibody anti-PtdIns(4,5)P2 (clone 2C11). The sections were then washed three times in PBS and incubated at room temperature with 3, 3-diaminobenzidine (Dako, Glostrup, Denmark).

###### 

List of primary antibodies

  Antigen         Clone               Isotype   Source          Animal   Dilution
  --------------- ------------------- --------- --------------- -------- ----------
  PtdIns(4,5)P2   Monoclonal (2C11)   IgM       Santa Cruz      Mouse    1:2000
  Annexin2        Polyclonal          IgG       Epitomics       Rabbit   1:100
  CHMP2B          Polyclonal          IgG       Abcam           Rabbit   1:600
  CDK5            Polyclonal (C-8)    IgG       Santa Cruz      Rabbit   1:200
  Flotillin-1     Monoclonal          IgG       BD bioscience   Mouse    1:200
  p-tau           Monoclonal (AT8)    IgG       Innogenetics    Mouse    1:800

We also performed haematoxylin and eosin (H&E) staining. After observing GVD bodies and NFTs in the hippocampus, we destained sections in absolute ethanol, and then processed them for PtdIns(4,5)P2 immunohistochemical analysis using the antibody 2C11. As controls, we prepared stained sections without primary antibody. In addition, we performed control experiments in which we blocked the immunogenicity of PtdIns(4,5)P2 with 10 mM neomycin sulphate/PBS prior to immunohistochemical staining with 2C11.

We also performed labelling of PtdIns(4,5)P2 using PLCδ~1~PH-GST on brain sections according to Watt *et al*. [@b22]. Briefly, sections were incubated in PBS for 10 min, PBS containing 0.2% Triton X-100, 3% fatty acid-free bovine serum albumin for 20 min and then with droplets of PLCδ~1~PH--GST (5 μg/ml) in PBS containing 0.2% Triton X-100, 3% bovine serum albumin for 2 h. Following washes in PBS, the GST was visualized using HRP conjugated anti-GST antibodies.

Immunofluorescence staining
---------------------------

We performed double staining on sections, including sections from the hippocampus and the parahippocampal gyrus, for further characterization. First, paraffin-embedded sections were irradiated with UV light overnight at 4°C to reduce autofluorescence by photobleaching tissue sections. After irradiation, we applied the same primary antibodies as described above. Some of these primary antibodies were detected using the following secondary antibodies (dilution 1:1000; Molecular Probes, Eugene, OR, USA): Alexa Fluor 488 donkey anti-mouse IgM and Alexa Fluor 548 donkey anti-rabbit IgG. The others were detected using the tyramide signal amplification (TSA) method with the same HRP-conjugated secondary antibodies as described above together with TSA™KIT \#12: Alexa Fluor 488 donkey and TSA™ KIT\#4: Alexa Fluor 568 donkey (Invitrogen™, Eugene, OR, USA). The slides were mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) and observed under an LSM510 confocal laser scanning microscope (Carl Zeiss AG, Oberkochen, Germany).

Moreover, we prepared 20-μm-thick paraffin-embedded sections and stained them using immunofluorescence techniques with 2C11 as primary antibody and Alexa Fluor 488 donkey anti-mouse IgM as secondary antibody for the construction of 3-dimensional images using an FV1000D confocal laser scanning microscope (Olympus, Tokyo, Japan).

Results
=======

PtdIns(4,5)P2 is a selective marker for both GVD bodies and NFTs
----------------------------------------------------------------

In the brains of AD cases, PtdIns(4,5)P2-positive structures were observed mainly in the hippocampal neurones. This staining pattern was reminiscent of those for GVD bodies and NFTs, appearing as accumulations of fine granules (Figures [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}). We classified the PtdIns(4,5)P2-positive cells in AD brains into three categories based on the structures they contained, as follows: GVD bodies, NFTs and 'GVD bodies + NFTs'. We reconstituted 3-dimensional images using confocal laser scanning microscopy (Figure [3](#fig03){ref-type="fig"}) and confirmed that these structures were consistent with GVD bodies and NFTs. The structures were immunopositive for PtdIns(4,5)P2 up to an antibody dilution of 1:8000, but were only faintly stained when the antibody was diluted to a ratio of 1:16 000. In other tauopathy cases such as MyD, CBD, PSP, PiD and PKAN, PtdIns(4,5)P2-positive structures were also observed in the hippocampal neurones, although they were fewer in number than they were in AD cases. In non-tauopathy cases such as PDD, MSA, ALS and control cases, PtdIns(4,5)P2-positive structures were observed only scarcely. In addition, we examined the brain stem and the spinal cord tissues of non-tauopathy cases and found no specific staining suggestive of Lewy bodies and no Bunina bodies, small eosinophilic neuronal inclusions commonly seen in patients with ALS, immunopositive for PtdIns(4,5)P2 (data not shown).

![Immunohistochemistry for PtdIns(4,5)P2. Immunohistochemistry in AD, MyD, ALS and control cases. AD case (case 1): low-power fields in hippocampus (a,b) and neocortex (c). MyD case (case 6): low-power fields in hippocampus (d,e) and neocortex (f). ALS case (case 17): low-power fields in hippocampus (g,h) and neocortex (i). Control case (case 26): low-power fields in hippocampus (j,k) and neocortex (l). AD case (case 5): some of the detected structures are (m) GVD bodies, (n) 'GVD bodies + NFTs', and (o) NFTs. The specificity of immunoreactivity for PtdIns(4,5)P2 was verified using PLCδ~1~PH-GST on sections, which showed essentially the same staining pattern as the anti-PtdIns(4,5)P2 antibody (p--r). Scale bars: (a--l) 50 μm, (m--r) 20 μm.](nan0040-0489-f1){#fig01}

![PtdIns(4,5)P2-positive structures corresponding to GVD bodies and NFTs. In the hippocampus of an AD case, the cellular localization of PtdIns(4,5)P2 was compared among haematoxylin and eosin (H&E)--stained sections (a,c), sections subjected to immunohistochemical analysis with 2C11 \[b,d; some of the structures are GVD bodies (arrowhead) and some are NFTs (arrow)\], sections incubated without primary antibody (e), and sections incubated with 10 mM neomycin sulphate/PBS prior to immunohistochemical staining with 2C11 (f). Scale bars: 20 μm.](nan0040-0489-f2){#fig02}

![Three-dimensional image of PtdIns(4,5)P2-positive structures in the hippocampus. PtdIns(4,5)P2-immunopositive structures in the hippocampus in an AD case (case 1). (a) 2-dimensional serial images and (b) reconstituted 3-dimensional image. Some of the structures are GVD bodies (arrowhead) and some are NFTs (arrow).](nan0040-0489-f3){#fig03}

The specificity of 2C11
-----------------------

The specificity of the anti-PtdIns(4,5)P2 antibody (clone 2C11) used in this study has been already reported; pre-incubation of the 2C11 antibody with an excess of liposomes containing different phosphoinositides showed that the specific staining was abolished by PtdIns(4,5)P2, but not by any other lipid, including PtdIns(3,4,5)P3, PtdIns(4,5)P2, PtdIns(3,4)P2 and PtdIns(3,5)P2 \[[@b23],[@b24]\]. Another study showed that binding of 2C11 was effectively prevented by incubation with neomycin, an aminoglycoside antibiotic that binds with high affinity to several phosphoinositides including PtdIns(4,5)P2, and that incubation with a GST-tagged PH domain of PLCδ~1~, which binds PtdIns(4,5)P2 with exquisite specificity, also reduced the intensity of staining by the 2C11 antibody \[[@b25]\]. We applied a GST-tagged PH domain of PLCδ~1~ directly onto tissue sections and visualized it using an HRP-conjugated anti-GST antibody. The staining pattern obtained by this method was essentially identical to that following immunohistochemistry using the 2C11 antibody (Figure [1](#fig01){ref-type="fig"}**p**--**r**). We also investigated the specificity of 2C11 for PtdIns(4,5)P2 using neomycin, a selective blocker of PtdIns(4,5)P2, and confirmed a lack of staining compared with positive controls (Figure [2](#fig02){ref-type="fig"}**f**). Furthermore, the presence of the PtdIns(4,5)P2-binding protein annexin 2 in GVD bodies and NFTs substantiates the specificity of the antibody. Taken together, our data suggested that PtdIns(4,5)P2 was specifically stained with the 2C11 antibody.

PtdIns(4,5)P2-positive structures identified by double immunofluorescence staining
----------------------------------------------------------------------------------

We performed double immunofluorescence staining for PtdIns(4,5)P2 and several established markers to characterize the PtdIns(4,5)P2-positive structures in AD cases. First we used anti-PtdIns(4,5)P2 antibody together with an anti-CHMP2B antibody as a GVD body marker, which revealed that some of the PtdIns(4,5)P2-immunopositive granules colocalized with CHMP2B (Figure [4](#fig04){ref-type="fig"}**a**). This result suggested that at least some PtdIns(4,5)P2-positive granules correspond to the intraluminal granules associated with GVD bodies.

![Representative confocal laser scanning micrograph. Double immunofluorescence labeling for (a) CHMP2B (green) and PtdIns(4,5)P2 (red), (b) AT8 (green) and PtdIns(4,5)P2 (red), (c,d) CDK5 (green) and PtdIns(4,5)P2 (red), (e,f) flotillin-1 (green) and PtdIns(4,5)P2 (red), and (g,h) annexin 2 (green) and PtdIns(4,5)P2 (red) and merged images in sections from patients with AD. For optimum visualization of the relationship, images from two channels were assigned the pseudocolour red \[568 nm, for PtdIns(4,5)P2 in (b) and (e,f)\] or green (488 nm, for AT8 and flotillin-1) and merged. Scale bars:10 μm.](nan0040-0489-f4){#fig04}

Next, we used anti-PtdIns(4,5)P2 antibody together with AT8 antibody as a NFT marker, which revealed that most NFTs were immunopositive for PtdIns(4,5)P2 (Figure [4](#fig04){ref-type="fig"}**b**). However, PtdIns(4,5)P2 and phosphorylated tau immunoreactivity patterns were not merged completely within each NFT, which means that while NFTs contain PtdIns(4,5)P2, it is segregated from AT8. The NFTs themselves showed accumulations of fine spherical granules and some granules were distributed diffusely within pyramidal neurones.

To identify the fine spherical granules, we performed double immunofluorescence staining using anti-PtdIns(4,5)P2 antibody and an anti-CDK5 antibody, which showed the colocalization on GVD bodies and fine granules, some of them in NFTs (Figure [4](#fig04){ref-type="fig"}**c**,**d**). It has been reported that fine spherical granules as well as GVD bodies and NFTs are all immunopositive for CDK5 \[[@b5]\]. To investigate whether these granules are related to lipid rafts we performed double immunofluorescence staining using anti-PtdIns(4,5)P2 antibody, anti-flotillin-1 antibody and anti-annexin 2 antibody, established raft-related proteins. This revealed the colocalization of PtdIns(4,5)P2 and lipid raft-related proteins in these fine spherical granules as well as in NFTs and GVD bodies (Figure [4](#fig04){ref-type="fig"}**e**--**h**).

Discussion
==========

In this study, we found that PtdIns(4,5)P2 is selectively enriched in both GVD bodies and NFTs. Based on a limited dilution analysis, the anti PtdIns(4,5)P2 antibody used showed the same sensitivity for GVD bodies and NFTs. The lack of background staining suggests that the concentration of PtdIns(4,5)P2 in these structures is much higher than the physiological level. Thereby, from the standpoint of lipid composition, GVD bodies and NFTs are related to each other. Of note, whereas immunoreactivity for PtdIns(4,5)P2 was evident in NFTs, PtdIns(4,5)P2 was segregated from tau within NFTs. This result is consistent with the previous report that flotillin-1 was not colocalized with tau in tangle-bearing neurones. In addition, it is of interest that PtdIns(4,5)P2-positive granules can occasionally be observed within and outside NFTs.

Physiologically, PtdIns(4,5)P2 is enriched in plasma membranes and intra-nuclear structures, and is involved in a variety of cellular functions, such as the internalization of GPI-anchored proteins, pre-mRNA processing, and activation of inward rectifier potassium channels \[[@b26]\]; however, in the present experimental condition, none of these structures were detected. In contrast, pathological accumulation of PtdIns(4,5)P2 was observed in cultured cells from patients with Lowe syndrome, an X-linked disorder that affects eyes, neurones and kidneys (OMIM 309000) \[[@b27]\]. Interestingly, loss of the causative gene OCRL resulted in the appearance of PtdIns(4,5)P2-positive giant cytoplasmic vacuoles \[[@b28]\]. In accordance with the granules reported by Girardot *et al*., PtdIns(4,5)P2-positive granules were shown to contain lipid raft compartments based on the findings that flottilin-1 and annexin 2 colocalized with them. Co-localization of CDK5 on these granules is in agreement with recent evidence that CDK5 is recruited to lipid rafts upon stimulation \[[@b29]\]. Funk *et al*. reported that GVD bodies are located in the endocytic pathway leading to lysosomal degradation via multivesicular bodies \[[@b30]\]. Although, PtdIns(3)P and PtdIns(3,5)P2 clearly mark endosomal and/or multivesicular bodies, a relatively small amount of PtdIns(4,5)P2 was also shown to be present in endocytic vesicles. Collectively, the PtdIns(4,5)P2-positive structures observed in tauopathies may have some relationship to endosomes.

Because the phosphorylation status of PtdIns can be altered along the course of vesicle transport, the presence of the same PtdIns on vesicles does not readily imply that the origin of vesicles is unique. CK1δ and CK1ε are seen in GVD bodies but not in NFTs \[[@b17]\], suggesting that GVD bodies and NFTs arise from two independent pathological processes. It is unlikely that such highly concentrated pools of PtdIns(4,5)P2 are synthesized from different sources by chance; therefore, there might be a common mechanism by which PtdIns(4,5)P2 accumulates within GVD bodies and NFTs. Moreover, immunohistochemistry of the hippocampus using the MPM2 antibody that recognizes a set of phosphoproteins in mitotic cells also revealed common antigenicity of GVD bodies and NFTs in accordance with our results. Conversely, phosphorylated ribosomal protein S6 (pS6), a specific marker for stress granules in model systems, localized to GVD bodies in AD hippocampi \[[@b31]\]. This phenomenon was more common in neurones not containing NFTs, suggesting that GVD bodies might be a morphologic checkpoint between cell death and reversible cellular stress. The differential distribution of CK isoforms is likely analogous to the endosomal sorting complex required for transport (ESCRT) pathway in which a distinct set of subunits is recruited onto vesicles sequentially, and might be associated with neuronal viability.

In conclusion, our data indicate that PtdIns(4,5)P2 as well as lipid raft-associated proteins might equally affect the formation of GVD bodies and NFTs. Lipid raft-associated materials might have roles in all processes of degeneration in AD. Further investigation of the lipid composition of these granules will enable us to elucidate more precisely the pathological mechanisms underlying AD.
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